ProHema: Interim Phase II data

Fate said an IDMC supported continuation of the open-label, U.S. Phase II PUMA trial evaluating a nutrient-rich media formulation

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE